

2017 was the best year for Sopharma AD after the crisis

Sofia, Bulgaria, January 30, 2018 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) ended its most successful financial year after the crisis. 2017 ended with 12.5% revenue growth reaching 205.3 million BGN, 44.8% increase in operating profit, 30.7% EBITDA growth and almost 10% growth in net profit.

During this successful year, the company took two important investment decisions, namely to start the construction of:

1. An extraction plant in Kazanlak, which will allow more effective and modern production of all phyto products and
2. A new lyophilic plant in Sofia, a necessary step for increasing the production capacity for the life-saving Methylprednisolone.

After nearly five years of low investment activity these projects are a logical continuation of the company's sustainable development program and our well-recognized social function in the healthcare sector in Bulgaria.


Pelagia Viatcheva
Investor Relations Director,
Sopharma AD


Information about the company

Sopharma AD

85 years tradition and modern approach – modern production, European quality standards, corporate social responsibility. Sopharma has an active and crucial role in raising standards of everyday life, in making people healthier, happier and safer. Sopharma AD continuously invests in technologies, innovation, research and science. We establish a constant and effective dialogue with all the actors in the pharmaceutical industry that contribute to the improvement of the health care system.

The company produces and markets medicinal substances and dosage forms; conducts research, engineering and implementation activities in the field of phytochemistry, chemistry and pharmaceuticals. Sopharma AD provides services related to production, as well as to ancillary and service activities.

The Company has a portfolio of more than 210 products: mainly generics and 15 original products, of which 12 products are phyto-based.

Sopharma Group

Sopharma Group is a vertically integrated healthcare business that operates in important sectors such as pharmaceuticals production, hospital supplies, pharmaceutical distribution (GDP standardized) and others. Sopharma and its production subsidiaries have 12 pharmaceutical plants in Bulgaria, complying with EU requirements – GMP and a factory in Ukraine certified by local authorities.

Sofia, Bulgaria
5 Lachezar Stanchev Str.
Sopharma Business Towers, Tower A

www.sopharmagroup.com
tel: +359 (0) 2 4055 200; +359 (0) 8134 200
fax: +359 (0) 2 4055 141; +359 (0) 8134 141